GeneDx Holdings Corp. (WGS) - Dilution Analysis

10-Q filing | 29.3M shares outstanding

10-Q filing | 28.8M shares outstanding

POS AM filing: This is a deregistration of unsold securities from a previous offering. The registrant is removing $74,935,250 of unsold securities from a registration statement filed on August 26, 2022.

10-Q filing | 28.1M shares outstanding

10-K filing | 26.9M shares outstanding

10-Q filing | 27.1M shares outstanding

10-Q filing | 26.6M shares outstanding

10-Q filing | 26.1M shares outstanding

10-K filing | 24.3M shares outstanding

10-Q filing | 25.8M shares outstanding

8-K filing: GeneDx Holdings Corp. entered into a Credit Agreement with Perceptive, issuing a warrant to purchase up to 1,200,000 shares of its Class A common stock, with an initial tranche of 800,000 shares vested at an exercise price of $3.1752 per share.

10-Q filing | 25.4M shares outstanding

10-Q filing | 25.6M shares outstanding

8-K filing: Stock split 1-for-33 | Outstanding: 798,247,286 → 24,186,892

10-K filing | 798.2M shares outstanding

8-K filing: GeneDx Holdings Corp. entered into agreements for offerings of 428,571,429 shares of Class A common stock at $0.35 per share through an underwritten public offering and a registered direct offering.

10-Q filing | 380.8M shares outstanding

S-3 filing: The company has filed a shelf registration statement on Form S-3 to offer Class A common stock, preferred stock, debt securities, warrants, subscription rights and/or units for up to a total dollar amount of $300,000,000.

S-3 filing: This is an S-3 filing for a shelf offering of Class A common stock and warrants by Selling Securityholders.

10-Q filing | 380.6M shares outstanding

10-Q filing | 377.2M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 160,864,198 shares of Class A common stock by selling stockholders.

8-K filing: Completion of acquisition of GeneDx business through merger, issuance of 80 million shares of Class A common stock to OPKO as part of the merger consideration, and concurrent private placement of 50 million shares of Class A common stock to institutional investors at $4.00 per share. ($200.0M proceeds)

POS AM filing: This is a prospectus for the offer and sale of common stock and warrants by selling securityholders.

10-K filing | 245.0M shares outstanding

8-K filing: Sema4 will acquire GeneDx through a merger, issuing 80 million shares of its Class A common stock to OPKO as part of the consideration, and also sell 50 million shares of Class A common stock to PIPE Investors at $4.00 per share for $200 million. ($200.0M proceeds)

10-Q filing | 241.3M shares outstanding

S-1 filing: This S-1 filing registers the offer and sale of Class A common stock and warrants by selling securityholders and the registrant, including shares issuable upon exercise of warrants.

10-Q filing | 44.3M shares outstanding

10-Q filing | 44.3M shares outstanding

10-K filing | 44.3M shares outstanding

8-K filing: CM Life Sciences, Inc. (CMLS) entered into a Merger Agreement with Mount Sinai Genomics, Inc., d/b/a Sema4, to acquire Sema4 through a merger, with CMLS changing its name to a name determined by Sema4. ($350.0M proceeds)

10-Q filing | 44.3M shares outstanding

8-K filing: CM Life Sciences, Inc. consummated its IPO of 44,275,000 units at $10.00 per unit, generating gross proceeds of $442,750,000, and completed a private sale of 7,236,667 warrants at $1.50 per warrant, generating gross proceeds of $10,855,000. ($453.61M proceeds)

S-1/A filing: The company is engaged in an initial public offering of units, each comprised of one share of Class A common stock and one-third of one Public Warrant.

S-1/A filing: This is an S-1/A filing for an initial public offering of units, each consisting of one share of Class A common stock and one-third of one redeemable warrant, with a total proposed amount of $350,000,000. The company is a blank check company focusing on the life sciences sector.

S-1 filing: CM Life Sciences, Inc. is offering 35,000,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-third of one redeemable warrant.